Fibrin D-dimer, Tissue Plasminogen Activator, Plasminogen Activator Inhibitor, and the Risk of Major Ischaemic Heart Disease in the Caerphilly Study

G. D. O. Lowe; J. W. G. Yarnell; P. M. Sweetnam; A. Rumley; H. F. Thomas; P. C. Elwood

doi:10.1055/s-0037-1614231

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(01): 129-133
DOI: 10.1055/s-0037-1614231

Review Article

Schattauer GmbH

Fibrin D-dimer, Tissue Plasminogen Activator, Plasminogen Activator Inhibitor, and the Risk of Major Ischaemic Heart Disease in the Caerphilly Study

G. D. O. Lowe

¹From the University Department of Medicine, Royal Infirmary, Glasgow

,

J. W. G. Yarnell

²From the MRC Epidemiology Unit (South Wales), Llandough Hospital, Penarth, UK

,

P. M. Sweetnam

²From the MRC Epidemiology Unit (South Wales), Llandough Hospital, Penarth, UK

,

A. Rumley

¹From the University Department of Medicine, Royal Infirmary, Glasgow

,

H. F. Thomas

²From the MRC Epidemiology Unit (South Wales), Llandough Hospital, Penarth, UK

,

P. C. Elwood

²From the MRC Epidemiology Unit (South Wales), Llandough Hospital, Penarth, UK

› Institutsangaben

Abstract

Summary

Plasma levels of fibrin D-dimer, tissue plasminogen activator (tPA) and plasminogen activator inhibitor (PAI) have been associated with ischaemic heart disease (IHD). However their associations with incident IHD in samples of the general population are not established. D-dimer antigen, tPA antigen and PAI activity were measured in stored, fasting plasma samples from 1,998 men aged 45-65 examined between 1984 and 1988, during the first re-examination of the Caerphilly Study cohort. These variables were related to major IHD events (myocardial infarction or IHD death) which occurred in 129 men during a follow-up period which averaged 61 months. Mean fibrin D-dimer was higher in men who developed IHD events (90 vs. 71 ng/ml; age-adjusted logarithmic mean difference 0.21; 95% CI 0.11, 0.30; p <0.0001). This association remained after adjusting for baseline IHD and for other risk factors including fibrinogen: the adjusted relative odds of IHD in the highest fifth of D-dimer were 3.5 (95% CI 1.8, 6.9; p = 0.0003). Mean tPA antigen was also higher in men who developed IHD (12.6 vs. 11.6 ng/ml; mean difference 0.9; 95% CI 0.2, 1.7; p = 0.02); however this difference largely disappeared after adjusting for other risk factors. PAI activity was not associated with risk of IHD.

Volltext

Referenzen

References
1 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
2 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor; a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 963-5.
3 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
4 Gaffney PJ, Brasher M. Subunit structure of the plasmin-induced degradation products of cross-linked fibrin. Biochem Biophys Acta 1973; 295: 308-13.
5 Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis?. Clin Sci 1995; 89: 205-14.
6 Lowe GDO, Rumley A, Balendra R, Lee AJ, Tunstall-Pedoe HD. Blood rheology and haemostasis in survivors of premature myocardial infarction: a case-control study. Thromb Haemost 1993; 69: 796.
7 Al-Zahrani H, Lowe GDO, Douglas JT, Cuschieri R, Pollock JG, Smith WCS. Increased fibrin turnover in peripheral arterial disease: comparison with a population study. Clin Hemorheol 1992; 12: 867-72.
8 Smith FB, Lowe GDO, Fowkes FGR, Rumley A, Rumley AG, Donnan PT, Housley E. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993; 102: 155-62.
9 Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995; 74: 828-32.
10 Lee AJ, Fowkes FGR, Rattray A, Rumley A, Lowe GDO. Haemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease. Br J Haematol 1996; 92: 226-30.
11 Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73: 527-33.
12 Woodburn KR, Lowe GDO, Rumley A, Love J, Pollock JG. Relation of haemostatic, fibrinolytic and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol 1995; 14: 346-52.
13 Smith FB, Lee AJ, Fowkes FGR, Rumley A, Lowe GDO. Smoking, haemostatic factors and the severity of aorto-iliac and femoro-popliteal disease. Thromb Haemost 1996; 75: 19-24.
14 Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, McGregor I, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-6.
15 Woodburn KR, Rumley A, Lowe GDO, Love JG, Murray GD, Pollock JG. Clinical, biochemical and rheologic factors affecting the outcome of infra-inguinal bypass grafting. J Vasc Surg 1996; 24: 639-46.
16 Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836-44.
17 Jansson J-H. The fibrinolytic system in ischaemic heart disease. In: Clinical Aspects of Fibrinolysis. Nilsson TK, Boman K, Jansson J-H. eds. Stockholm: Almqvist and Wiksell; 1991: 95-110.
18 Smith FB, Lee AJ, Rumley A, Fowkes FGR, Lowe GDO. Tissue plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995; 115: 35-43.
19 Jansson J-H, Oloffson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a seven year follow-up. Circulation 1993; 88: 2030-4.
20 Thomson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
21 Hamsten A, Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-8.
22 Bainton D, Miller NE, Bolton CH, Yarnell JWG, Sweetnam PM, Baker IA, Lewis B, Elwood PC. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell collaborative heart disease studies. Br Heart J 1992; 68: 60-6.
23 Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bul Wld Hlth Org 1962; 645-58.
24 World Health Organisation Regional Office for Europe.. Myocardial infarction community registers. Copenhagen: WHO; Public Health in Europe no 5, 1976.
25 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. Increased fibrin turnover and high PAI-1 activity as predictors of ischaemic events in atherosclerotic patients: a case-control study. Arteriosclerosis Thrombosis 1993; 13: 1412-7.
26 Lip GYH, Zafiris J, Watson RDS, Bareford D, Lowe GDO, Beevers DG. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-31.
27 Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation products (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-40.
28 Jansson JG, Nilsson TK, Olofsson BO. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
29 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
30 Meade TW, Howarth DJ, Cooper J, MacCallum PK, Stirling Y. Fibrinolytic activity and arterial disease. Lancet 1994; 343: 1442.
31 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. A prospective study of plasminogen activator inhibitor and the risk of future myocardial infarction. Circulation. 1992 (suppl I) I-325 (abstr).
32 Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Haemostas 1990; 16: 207-16.
33 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
34 Giansante C, Fiotti N, Calabrese S, La Verde R, Pandullo C, Scardi S, Guarnieri G. D-dimer and anticoagulation in patients with mechanical prosthetic heart valves. A 2-year follow-up. Arterioscler Thromb Vasc Biol 1997; 17: 1320-4.